Nasdaq
$15.48▲ 0.16%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.01BShares out 7.800M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 6d agoPre-market26.10.19 20:01DEF 14AOther#●●●
Summit Therapeutics Inc.
Summit Therapeutics will hold a special meeting of stockholders on November 4, 2026, to vote on an amendment to increase the number of authorized shares of common stock by 1 billion, from 1 billion to 2 billion. As of October 1, 2026, the company had 799,726,418 shares of common stock outstanding.…more
$15.48+0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 05:074Ownership
Summit Therapeutics Inc.
Insider Anand Bhaskar of Summit Therapeutics Inc. filed a Form 4 on October 14, 2026, reporting a change in beneficial ownership of securities as of October 8, 2026. This filing serves as an official disclosure of insider stock activity to the SEC.…more
$15.48+0.16%vs prev closeView filingShare - 10.6After-hours26.10.07 06:03PRE 14AOther
Summit Therapeutics Inc.
Summit Therapeutics Inc. will hold a special meeting of stockholders to approve an amendment to its certificate of incorporation, which increases the number of authorized shares of common stock by 1 billion, from 1 billion to 2 billion. This proposal is intended to modify the company's capital structure, and shareholders are requested to vote on the amendment.…more
$15.48+0.16%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoAfter-hours26.10.24 05:41#●●●#●●●#●●●
Summit Therapeutics and Lunit Announce Research Agreement for Immuno-Oncology Development…more
Summit Therapeutics will utilize Lunit's AI solution to analyze the tumor microenvironment for its immuno-oncology drug, Ivonescimab. This partnership aims to support the development programs of Summit through advanced AI analysis.…more
$15.48+0.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.21 19:07
●●●●●●●● ●●●●● ●●●●●●
Summit Therapeutics is collaborating with ECOG-ACRIN to evaluate the safety and efficacy of ivonescimab in a Phase II/III study for patients with advanced biliary tract cancer. The study aims to compare the novel therapeutic approach against current standard-of-care immunotherapy regimens.…more
$15.48+0.16%vs prev closeShareBenzinga - 6d agoPre-market26.10.19 20:07
●●●●●●●● ●●●●● ●●●●●●
Summit Therapeutics has launched a global Phase II clinical trial for ivonescimab in patients with advanced clear cell renal cell carcinoma. The trial evaluates the drug both as a monotherapy and in combination with other treatments.…more
$15.48+0.16%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report